Serotype of adenovirus and uses thereof

Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S320100

Reexamination Certificate

active

10951102

ABSTRACT:
The invention provides a gene delivery vehicle and a gene of interest comprising at least one Ad35 element or a functional equivalent thereof, responsible for avoiding or diminishing neutralizing activity against adenoviral elements by the host to which the gene is to be delivered. A functional equivalent/homologue of an Ad35 (element) includes an adenovirus (element) which, like adenovirus 35, encounters pre-existing immunity in less than about 10% of the hosts to which it is administered for the first time, or which is capable in more than about 90% of the hosts to which it is administered of avoiding or diminishing the immune response.

REFERENCES:
patent: 4487829 (1984-12-01), Sharp et al.
patent: 4517686 (1985-05-01), Ruoslahti et al.
patent: 4578079 (1986-03-01), Ruoslahti et al.
patent: 4589881 (1986-05-01), Pierschbacher et al.
patent: 4593002 (1986-06-01), Dulbecco
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 4797368 (1989-01-01), Carter et al.
patent: 4956281 (1990-09-01), Wallner et al.
patent: 5024939 (1991-06-01), Gorman
patent: 5096815 (1992-03-01), Ladner et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5198346 (1993-03-01), Ladner et al.
patent: 5204445 (1993-04-01), Plow et al.
patent: 5223394 (1993-06-01), Wallner
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5240846 (1993-08-01), Collins et al.
patent: 5246921 (1993-09-01), Reddy et al.
patent: 5332567 (1994-07-01), Goldenberg
patent: 5349053 (1994-09-01), Landolfi
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5436146 (1995-07-01), Shenk et al.
patent: 5443953 (1995-08-01), Hansen et al.
patent: 5474935 (1995-12-01), Chatterjee et al.
patent: 5521291 (1996-05-01), Curiel et al.
patent: 5534423 (1996-07-01), Plasson et al.
patent: 5543328 (1996-08-01), Mcclelland et al.
patent: 5547932 (1996-08-01), Curiel et al.
patent: 5552311 (1996-09-01), Sorscher et al.
patent: 5559099 (1996-09-01), Wickham et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5622699 (1997-04-01), Ruoslahti et al.
patent: 5712136 (1998-01-01), Wickham et al.
patent: 5731190 (1998-03-01), Wickham et al.
patent: 5756086 (1998-05-01), Mcclelland et al.
patent: 5770442 (1998-06-01), Wickham et al.
patent: 5837511 (1998-11-01), Falck-Pedersen et al.
patent: 5846782 (1998-12-01), Wickham et al.
patent: 5849561 (1998-12-01), Falck-Pedersen
patent: 5856152 (1999-01-01), Wilson et al.
patent: 5871727 (1999-02-01), Curiel
patent: 5871982 (1999-02-01), Wilson et al.
patent: 5877011 (1999-03-01), Armentano et al.
patent: 5922315 (1999-07-01), Roy
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 6033908 (2000-03-01), Bout et al.
patent: 6057155 (2000-05-01), Wickham et al.
patent: 6100086 (2000-08-01), Kaplan et al.
patent: 6127525 (2000-10-01), Crystal et al.
patent: 6287857 (2001-09-01), O'riordan et al.
patent: 6306652 (2001-10-01), Fallaux et al.
patent: 6486133 (2002-11-01), Herlyn et al.
patent: 6492169 (2002-12-01), Vogels et al.
patent: 6669942 (2003-12-01), Perricaudet et al.
patent: 6913922 (2005-07-01), Bout et al.
patent: 259212 (1987-08-01), None
patent: 1016726 (1998-12-01), None
patent: 99201545.3 (1999-05-01), None
patent: 1067188 (1999-07-01), None
patent: 1020529 (1999-11-01), None
patent: 0 978 566 (2000-02-01), None
patent: 1 054 064 (2000-11-01), None
patent: WO91/00360 (1991-01-01), None
patent: WO91/05805 (1991-05-01), None
patent: WO91/05871 (1991-05-01), None
patent: WO92/02553 (1992-02-01), None
patent: WO92/13081 (1992-08-01), None
patent: WO93/03769 (1993-03-01), None
patent: WO93/06223 (1993-04-01), None
patent: WO93/07282 (1993-04-01), None
patent: WO93/07283 (1993-04-01), None
patent: WO94/08026 (1994-04-01), None
patent: WO94/10323 (1994-05-01), None
patent: WO94/11506 (1994-05-01), None
patent: WO94/15644 (1994-07-01), None
patent: WO94/17832 (1994-08-01), None
patent: WO94/24299 (1994-10-01), None
patent: WO94/26915 (1994-11-01), None
patent: WO95/05201 (1995-02-01), None
patent: WO95/06745 (1995-03-01), None
patent: WO95/14785 (1995-06-01), None
patent: WO95/16037 (1995-06-01), None
patent: WO95/21259 (1995-08-01), None
patent: WO95/26412 (1995-10-01), None
patent: WO95/27071 (1995-10-01), None
patent: WO96/13598 (1995-10-01), None
patent: WO95/31187 (1995-11-01), None
patent: WO95/31566 (1995-11-01), None
patent: WO96/00326 (1996-01-01), None
patent: WO96/00790 (1996-01-01), None
patent: WO96/07739 (1996-03-01), None
patent: WO96/10087 (1996-04-01), None
patent: WO96/12030 (1996-04-01), None
patent: WO96/13597 (1996-05-01), None
patent: WO96/14837 (1996-05-01), None
patent: WO97/12986 (1996-05-01), None
patent: WO96/17073 (1996-06-01), None
patent: WO96/18740 (1996-06-01), None
patent: WO96/24553 (1996-08-01), None
patent: WO96/26281 (1996-08-01), None
patent: WO96/35798 (1996-11-01), None
patent: WO97/00326 (1997-01-01), None
patent: WO98/22609 (1997-04-01), None
patent: WO97/20575 (1997-06-01), None
patent: WO97/38723 (1997-10-01), None
patent: WO98/07865 (1998-02-01), None
patent: WO98/11221 (1998-03-01), None
patent: WO98/13499 (1998-04-01), None
patent: WO98/32842 (1998-07-01), None
patent: WO98/40509 (1998-09-01), None
patent: WO98/49300 (1998-11-01), None
patent: WO98/50053 (1998-11-01), None
patent: WO99/32647 (1999-07-01), None
patent: WO99/47180 (1999-09-01), None
patent: WO99/55132 (1999-11-01), None
patent: WO99/58646 (1999-11-01), None
patent: WO 00/03029 (2000-01-01), None
patent: WO 00/24730 (2000-05-01), None
patent: WO 00/31285 (2000-06-01), None
patent: WO 00/52186 (2000-09-01), None
patent: WO 00/70071 (2000-11-01), None
patent: WO 01/04334 (2001-01-01), None
patent: WO 01/90158 (2001-11-01), None
patent: WO 02/24730 (2002-03-01), None
patent: WO 02/27006 (2002-04-01), None
Flomenberg et al., “Sequence and genetic Organization of Adenovirus Type 35 Early Region 3,” Journal of Virology, Nov. 1988, pp. 4431-4437, vol. 62, No. 11.
Gahery-Segard et al., “Immune response to recombinant Capsid Proteins of Adenovirus in Humans: Antifiber and Anti-Penton Base Antibodies Have a Synergistic Effect on Neutralizing Activity,” Journal of Virology, Mar. 1998, pp. 2388-2397, vol. 72, No. 3.
Notice of Opposition to a European Patent, Patent No. 1054064, by Cell Genesys Inc., dated Jul. 5, 2005.
Rosenfeld et al., Adenovirus-Mediated Transfer of a recombinant alpha-1-Antitrypsin Gene to the Lung Epithelium in Vivo, Science, Apr. 19, 1991, pp. 431-434, vol. 252.
Roy et al., “Circumvention of Immunity to the Adenovirus major Cost Protein Hexon,” Journal of Virology, Aug. 1998, pp. 6875-6879, vol. 72, No. 8.
Stevenson et al., “Human Adenovirus Serotypes 3 and 5 Bind to Two Different Cellular receptors via the Fiber Head Domain,” Journal of Virology, May 1995, pp. 2850-2857, vol. 69, No. 5.
Stratford-Perricaudet et al., “Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector,” Human Gene Therapy, 1990, pp. 241-256, vol. 1.
Abrahamsen et al., “Construction of an Adenovirus Tpe 7a E1A Vector,” Journal of Virology, Nov. 1997, p. 8946-8951 vol. 71, No. 11.
Albiges-Rizo et al., “Human Adenovirus Serotype 3 Fiber Protein,” Journal of Biological Chemistry, 266(6), 3961-3967 (1991).
Athappilly et al., “The Refined Crystal Structure of Hexon, the Major Coat Protein of Adenovirus Type 2, at 2·9 A Resolution,” J. Mol. Biol. (1994) 242, 430-455.
Bai et al., “Mutations That Alter an Arg-Gly-Asp (RGD) Sequence in the Adenovirus Type 2 Penton Base Protein Abolish Its Cell-Rounding Activity and Delay Virus Reproduction in Flat Cells,” Journal of Virology, 67(9), 5198-5205 (1993).
Bailey et al., “Phylogenetic Relationships among Adenovirus Serotypes,” Virology, 205, 439-452 (1994).
Ball-Goodrich et al., “Parvoviral Target Cell Specificity: Acquisition of Fibrotropism by a Mutant of the Lymphotropic Strain of Minute Virus of Mice Involves Multiple Amino Acid Substitutions within the Capsid,” Virology, 184, 175-186 (1991).
Basler et al., “Subgroup B Adenovirus Type 35 Early Region 3

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Serotype of adenovirus and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Serotype of adenovirus and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serotype of adenovirus and uses thereof will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3786488

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.